Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-07-20
2009-06-23
Nashed, Nashaat T (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S324000
Reexamination Certificate
active
07550427
ABSTRACT:
Disclosed are compounds that comprise: (i) a Kunitz domain polypeptide that comprises a Kunitz domain that binds to and inhibits a protease; and (ii) a plurality of polyethylene glycol moieties attached to the Kunitz domain polypeptide. Each accessible primary amine of the Kunitz domain polypeptide can be attached to one of the moieties. Also disclosed are related methods.
REFERENCES:
patent: 5166133 (1992-11-01), Houston et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5278144 (1994-01-01), Wolf et al.
patent: 5278285 (1994-01-01), Ebbers et al.
patent: 5373090 (1994-12-01), Norris et al.
patent: 5446090 (1995-08-01), Harris
patent: 5576294 (1996-11-01), Norris et al.
patent: 5583107 (1996-12-01), Wolf et al.
patent: 5589359 (1996-12-01), Innis et al.
patent: 5663143 (1997-09-01), Ley et al.
patent: 5672662 (1997-09-01), Harris et al.
patent: 5695760 (1997-12-01), Faanes et al.
patent: 5696088 (1997-12-01), Innis
patent: 5719041 (1998-02-01), Lazarus et al.
patent: 5736364 (1998-04-01), Kelley et al.
patent: 5739208 (1998-04-01), Harris
patent: 5780265 (1998-07-01), Denis et al.
patent: 5786328 (1998-07-01), Denis et al.
patent: 5795865 (1998-08-01), Markland et al.
patent: 5795954 (1998-08-01), Lazarus et al.
patent: 5804376 (1998-09-01), Braxton et al.
patent: 5843895 (1998-12-01), Lazarus et al.
patent: 5853723 (1998-12-01), Jacobs et al.
patent: 5900461 (1999-05-01), Harris
patent: 5932462 (1999-08-01), Harris
patent: 5990237 (1999-11-01), Bentley et al.
patent: 5994125 (1999-11-01), Markland et al.
patent: 6001596 (1999-12-01), Hillman et al.
patent: 6004579 (1999-12-01), Bathurst et al.
patent: 6010880 (2000-01-01), Markland et al.
patent: 6013448 (2000-01-01), Braxton et al.
patent: 6057287 (2000-05-01), Markland et al.
patent: 6071723 (2000-06-01), Markland et al.
patent: 6087473 (2000-07-01), Conklin et al.
patent: 6103499 (2000-08-01), Markland et al.
patent: 6113896 (2000-09-01), Lazarus et al.
patent: 6180607 (2001-01-01), Davies et al.
patent: 6214966 (2001-04-01), Harris
patent: 6258351 (2001-07-01), Harris
patent: 6333402 (2001-12-01), Markland et al.
patent: 6348558 (2002-02-01), Harris et al.
patent: 6362254 (2002-03-01), Harris et al.
patent: 6362276 (2002-03-01), Harris et al.
patent: 6376604 (2002-04-01), Kozlowski
patent: 6413507 (2002-07-01), Bentley et al.
patent: 6423498 (2002-07-01), Markland et al.
patent: 6432397 (2002-08-01), Harris
patent: 6455639 (2002-09-01), Yasukohchi et al.
patent: 6515100 (2003-02-01), Harris
patent: 6576235 (2003-06-01), Williams et al.
patent: 6610281 (2003-08-01), Harris
patent: 6624246 (2003-09-01), Kozlowski
patent: 6664331 (2003-12-01), Harris et al.
patent: 6710125 (2004-03-01), Kozlowski
patent: 6774180 (2004-08-01), Kozlowski et al.
patent: 6783965 (2004-08-01), Sherman et al.
patent: 6814982 (2004-11-01), Poncin et al.
patent: 6989369 (2006-01-01), Ladner et al.
patent: 7078383 (2006-07-01), Ley et al.
patent: 2002/0102703 (2002-08-01), Sheppard et al.
patent: 2002/0111460 (2002-08-01), Holloway
patent: 2003/0100070 (2003-05-01), Holloway et al.
patent: 2003/0153046 (2003-08-01), Jensen et al.
patent: 2003/0175919 (2003-09-01), Ley et al.
patent: 2003/0223977 (2003-12-01), Ley et al.
patent: 2004/0038893 (2004-02-01), Ladner et al.
patent: 2004/0049018 (2004-03-01), Bailon et al.
patent: 2004/0053206 (2004-03-01), Cicardi et al.
patent: 2004/0062746 (2004-04-01), Martinez et al.
patent: 2004/0062748 (2004-04-01), Martinez et al.
patent: 2004/0106747 (2004-06-01), Bailon et al.
patent: 2004/0126361 (2004-07-01), Saifer et al.
patent: 2004/0171794 (2004-09-01), Ladner et al.
patent: 2006/0228331 (2006-10-01), Peschke et al.
patent: 2007/0020252 (2007-01-01), Ladner et al.
patent: 2007/0065407 (2007-03-01), Patten et al.
patent: 2007/0100133 (2007-05-01), Beals et al.
patent: 301 122 (1989-02-01), None
patent: WO 93/14120 (1993-07-01), None
patent: WO 93/14121 (1993-07-01), None
patent: WO 93/14122 (1993-07-01), None
patent: WO 95/21601 (1995-08-01), None
patent: 9620278 (1996-07-01), None
patent: 02092147 (2002-11-01), None
patent: 02094200 (2002-11-01), None
patent: 2005021556 (2005-03-01), None
patent: 2005021557 (2005-03-01), None
patent: WO 2005/021556 (2005-03-01), None
Appendix A—alignment of SEQ ID No. 23 (DX-890) and SEQ ID No. 12 (ITI-2). No date.
Basu, A., et al., 2006, “Structure-function engineering of interferon-[beta]-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation”, Bioconjugate Chemistry, vol. 17, pp. 618-630.
Dhalluin, C., et al., 2005, “Structural, Kinteic, and thermodynamic analysis of the binding of the 40kDa PEG-interferon-[alpha]-2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2”, Bioconjugate Chemistry, vol. 16, pp. 518-527.
Cantor, et al., “Elastin and Elastases in Lung Disease”, Chapter 16, vol. II, p. 159-168.
Depiopharm Brochure “Engineered Protein Inhibitor of Human Neutrophil Elastase EPI-hNE4 (DX-890)” Dated Oct. 2004, printed from www.debio.com/e/pdf/fiche—epi—hne4—e.pdf.
Delacourt et al. “Protection against acute lung injury by intravenons or intratracheal pretreatment with EPI-HNE-4, a new potent neutrophil elastase inhibitor.” Am J Respir Cell Mol Biol. Mar. 2002;26(3):290-7.
Delgado et al., “The Uses and Properties of PEG-linked Proteins”, Critical Review in Therapeutic Drug Carrier Systems, vol. 9, Nos. 3, 4, pp. 249-304, (1992).
Donnelly et al. (2003) “Therapy for chronic obstructive pulmonary disease in the 21stcentury”Drugs63:1973-98.
Goodson, R. et al., “Site-Directed Pegylation of Recombinant Interleukin-2 at its Glycosylation Site”, Bio Technology, vol. 8, 343-346, (1990).
Katre, N. V. et al., “Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model”, Proc. Natl. Acad. Sci., 84, 1487-1491, (1987).
Katre N. V., J., “Immunogenicity of Recombinant Il-2 Modified by Covalent Attachment of Polyethylene Glycol”. Immunol. 144:209-213 (1990).
Kelly, et al., “Diabetes Insipidus in Uricase-Deficient Mice: A Model for Evaluating Therapy with Poly(Ethylene Glycol)-Modified”, J Am Soc Nephrol. 12:1001-1009, (2001).
Markland W et al., “Selection for protease inhibitors using bacteriophage display. ” Methods Enzymol. 1996;267:28-51.
Maxfield, et al., “Conformation of poly(ethylene oxide) in the solid state, melt and solution measured by Raman scattering”, Polymer 16,505-509 (1975).
Molineux, “Pegylation: Engineering Improved Pharmaceuticals for Enhanced Therapy”, Cancer Treatment Reviews, Apr. 2002, 28, Supplement A: 13-16.
Poznansky, M. J. et al., “Growth hormone-albumin conjugates Reduced renal toxicity and altered plasma clearance”, vol. 239:18-22 (1988).
Roberts, et al., “Chemistry for peptide and protein PEGylation”, Advanced Drug Delivery Reviews 54:459-476 (2002).
Abuchowski, A. et al., “Alteration of Immunological Properties of Bovine-Serum Albumin by Covalent Attachment of Polyethylene Glycol”, J. Bio. Chem., 252, 3578-3581, (1977).
Abuchowski, A. et al., “Cancer Therapy with Chemically Modified Enzymes. I. Antitumor Properties of Polyethylene Glycol-Asparaginase Conjugates”, Cancer Biochem. Biophys. vol. 7, 175-186, (1984).
Abuchkowski, A. et al., “Effect of Covalent Attachment of Polyethylene Glycol on Immunogenicity and Circulating Life of Bovine”, J. Biol. Chem. 252:3582-3586 (1977).
Sherman, et al., Chapter 11: “Conjugation of High-Molecular Weight Poly(ethylene glycol) to Cytokines: Granulocyte-Macrophage Colony-Stimulating Factors as Model Substrates”, American Chemical Society, 155-169 (1997).
Travis, et al., “Pulmonary Perspective: Potential Problems in Designing Elastase Inhibitors for Therapy”, Am. Rev. Respir. Dig. 143: 1412-1415 (1991).
Wark et al.
Ladner Robert C.
Ley Arthur C.
Sato Aaron K
Stochl Mark
Dyax Corp.
Lowrie Lando & Anastasi, LLP
Moore William W
Nashed Nashaat T
LandOfFree
Poly-pegylated protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Poly-pegylated protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Poly-pegylated protease inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4136517